Management of Heart Failure: Time to Consider New Options?
Faculty: Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI - Mikhail Kosiborod, MDMay 20, 2021
View this accredited e-learning program with a focus on heart failure at our partner website ReachMD, a leading online learning platform for physicians and other healthcare professionals
Derangements in potassium levels are associated with poor outcomes in patients with heart failure. At the same time, suboptimal use of renin-angiotensin-aldosterone system inhibitor (RAASi) therapies is associated with an increased risk of death. So how do we as clinicians balance these risks?
This discussion focuses on how providers can maximize the use of RAASi therapies in patients with heart failure while simultaneously employing potassium binders to manage hyperkalemia.
Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI, Professor and Chair of Medicine, University of Limerick (UL) School of Medicine & University Hospital Limerick, Ireland
- Mikhail Kosiborod, MD, Professor of Medicine, Saint Luke's Hospital of Kansas City, Kansas City, MO, USA
This activity is supported by an independent educational grant from Vifor Pharma.
Share this page with your colleagues and friends: